Benevolent AI (Benevolent AI) Current Accrued Expense : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Benevolent AI Current Accrued Expense?

Benevolent AI's Current Accrued Expense for the quarter that ended in Dec. 2023 was $0.00 Mil.

Benevolent AI Current Accrued Expense Historical Data

The historical data trend for Benevolent AI's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Current Accrued Expense Chart

Benevolent AI Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

Benevolent AI Quarterly Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial				-	-	-	-	-

Benevolent AI Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Benevolent AI Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Benevolent AI's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Benevolent AI (Benevolent AI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

BAI:Netherlands 2XA:Germany

Address

4-8 Maple Street, London, GBR, W1T 5HD

Website

https://www.benevolent.com

Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.